Misha V. Blagosklonny graduated with an MD and PhD from First Pavlov State Medical
University of St. Petersburg, RUS. Dr. Misha V. Blagosklonny has then
Moved to the USA, where he received the prestigious Fogarty Fellowship from the National Institutes of Health.
Within the period of his fellowship in Leonard Neckers’ laboratory at the National
Cancer Institute (NCI), he was a co-author of 18 publications on
Various biomedical topics, like targeting
HSP90, p53, Bcl2, Erb2, and Raf-1. He also was the last author for a clinical phase I/II
Trial paper.
After authoring seven papers within the period of a brief yet fruitful
Senior research fellowship in the El-Deiry Cancer Research Lab at the University of Pennsylvania,
Dr. Blagosklonny returned to NCI to cooperate with Tito Fojo. Together, they
Published 26 papers. Moreover, Dr. Misha Blagosklonny published anumber of experimental research papers and theoretical papers as lead
Author. Those sole-author publications
Encompassed two crucial themes.
The first of those explained selectively killing cancer
Cells with deregulated cell cycle or drug resistance via
Validation their resistance. The outcomes and underlying
Concept were so revolutionary that they were incorrectly cited by
Other scientists as “reversal of resistance, ” even though the paper was
Titled, “Exploiting of drug resistance instead of its reversal. ” One great
Supporter of this concept was the world-famous scientist Arthur Pardee, with whom Dr.
Blagosklonny co-authored a joint paper in 2001.
The second theme throughout Dr. Blagosklonny’s sole-author articles
Is a research method to create knowledge by
Uniting a few facts together from seemingly unrelated areas.
This results in new concepts with testable predictions, which in
Turn can be “tested” via analyzing the literature further. Once again, the
Notion was co-authored by Arthur Pardee in a 2002 publication in Nature. The
First success of the new research methodology was the description of the feedback
Regulation of p53, as supported by the discovery of mdm2/p53 loop; and the
Explanation why mutant p53 is always overexpressed, published in 1997. The most
Significant result revealed by Dr.
Blagosklonny’s research methodology is the hyperfunction (or quasi-programmed)
Theory of aging and the revelation of rapamycin as an exclusively well-tolerated
Anti-aging drug, published in 2006. As mentioned in Scientific American,
Michael Hall, who discovered mTOR in 1991, gives Dr. Blagosklonny recognition for
“connecting dots that others don' t even see. ”
In 2002, Dr. Blagosklonny became associate professor of medicine at New York Medical College.
He went on to assume responsibilities as a senior scientist at Ordway
Research Institute in Albany, New York, in 2005, before accepting another
Position at Roswell Park Cancer Institute as professor of oncology in 2009.
Since joining Roswell Park Comprehensive Cancer Center in 2009, Dr. Blagosklonny
Has studied the prevention of cancer (an age-related disease) by
Stopping organism aging — in other words, “preventing cancer
Via staying young. ” His laboratory closely worked together with
Andrei Gudkov’s and completed research on the suppression of
Cellular senescence, namely suppression of cellular conversion from healthy quiescence to
Permanent senescence. This led to the discovery of additional anti-aging
Medicines besides rapamycin. The cell culture studies were
Complemented by studies in mice, including a few models like
Standard and aging mice, p53-deficient mice, and mice on a high-fat diet.
Dr. Mikhail Blagosklonny has also published extensively on the stoppage of cellular
Senescence via rapamycin and other mTOR inhibitors, life
Extension and cancer stoppage in mice, and combinations of anti-
Aging medicines to be taken by humans. A
Rapamycin-based combination of seven clinically available drugs has
Been named the “Koschei Formula” and is now utilized for the treatment of aging in patients
At the Alan Green Clinic in Little Neck, New York.
| 
